What is a stock summary page? Click here for an overview.
Business Description
Dianthus Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US2528281080
Compare
Compare
Traded in other countries / regions
DNTH.USA87E.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2023-09-12Description
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 184.6 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 16.24 | |||||
| Beneish M-Score | 13.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.2 | |||||
| 3-Year EBITDA Growth Rate | -51.1 | |||||
| 3-Year EPS without NRI Growth Rate | -42.5 | |||||
| 3-Year FCF Growth Rate | -51.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -16.36 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.77 | |||||
| 9-Day RSI | 32.11 | |||||
| 14-Day RSI | 37.73 | |||||
| 3-1 Month Momentum % | -3.93 | |||||
| 6-1 Month Momentum % | -17.57 | |||||
| 12-1 Month Momentum % | -29.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.22 | |||||
| Quick Ratio | 15.22 | |||||
| Cash Ratio | 14.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.1 | |||||
| Shareholder Yield % | -44.71 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1633.75 | |||||
| Net Margin % | -1362.78 | |||||
| FCF Margin % | -1255.57 | |||||
| ROE % | -26.72 | |||||
| ROA % | -25.61 | |||||
| ROIC % | -271.06 | |||||
| 3-Year ROIIC % | -89.87 | |||||
| ROC (Joel Greenblatt) % | -11460.85 | |||||
| ROCE % | -31.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 97.29 | |||||
| PB Ratio | 1.61 | |||||
| Price-to-Tangible-Book | 1.61 | |||||
| EV-to-EBIT | -3.43 | |||||
| EV-to-EBITDA | -3.45 | |||||
| EV-to-Revenue | 56.1 | |||||
| EV-to-Forward-Revenue | 87.45 | |||||
| EV-to-FCF | -4.47 | |||||
| Price-to-Net-Current-Asset-Value | 2.19 | |||||
| Price-to-Net-Cash | 2.24 | |||||
| Earnings Yield (Greenblatt) % | -29.15 | |||||
| FCF Yield % | -13.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DNTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dianthus Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.235 | ||
| EPS (TTM) ($) | -2.6 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 49.25 | ||
| 14-Day RSI | 37.73 | ||
| 14-Day ATR ($) | 1.850574 | ||
| 20-Day SMA ($) | 21.496 | ||
| 12-1 Month Momentum % | -29.01 | ||
| 52-Week Range ($) | 18.13 - 32.29 | ||
| Shares Outstanding (Mil) | 32.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dianthus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dianthus Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dianthus Therapeutics Inc Frequently Asked Questions
What is Dianthus Therapeutics Inc(DNTH)'s stock price today?
The current price of DNTH is $18.29. The 52 week high of DNTH is $32.29 and 52 week low is $18.13.
When is next earnings date of Dianthus Therapeutics Inc(DNTH)?
The next earnings date of Dianthus Therapeutics Inc(DNTH) is 2025-05-09 Est..
Does Dianthus Therapeutics Inc(DNTH) pay dividends? If so, how much?
Dianthus Therapeutics Inc(DNTH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers